What is the recommended diagnostic work‑up and treatment algorithm for overt hypothyroidism, overt hyperthyroidism, subclinical hypothyroidism, and subclinical hyperthyroidism in adults, including dosing of levothyroxine, methimazole, propylthiouracil, and indications for radioactive iodine or thyroidectomy, with special considerations for pregnancy, elderly patients, coronary artery disease, atrial fibrillation, and osteoporosis?

Comprehensive Thyroid Treatment Algorithm

Overt Hypothyroidism (Elevated TSH + Low Free T4)

Initiate levothyroxine immediately for all patients with overt hypothyroidism—this is non-negotiable regardless of symptom severity. 1, 2

Critical Safety First: Rule Out Adrenal Insufficiency

• Before starting levothyroxine, measure morning cortisol and ACTH in patients with suspected central hypothyroidism, autoimmune disease, or hypopituitarism—initiating thyroid hormone before corticosteroid replacement can trigger life-threatening adrenal crisis. 1, 3
• If adrenal insufficiency is confirmed, start hydrocortisone 20 mg morning/10 mg afternoon for at least one week before levothyroxine. 1

Initial Levothyroxine Dosing

For patients <70 years without cardiac disease:

• Start full replacement dose of 1.6 mcg/kg/day (typically 75-100 mcg daily). 1, 3, 4
• This achieves faster normalization and avoids prolonged hypothyroid state. 1

For patients >70 years OR with coronary artery disease, atrial fibrillation, or heart failure:

• Start 25-50 mcg daily to avoid unmasking cardiac ischemia or precipitating arrhythmias. 1, 3, 5, 2, 4
• Increase by 12.5-25 mcg every 6-8 weeks based on TSH response. 1, 3
• Elderly patients with coronary disease face real risk of myocardial infarction or fatal arrhythmias if started at full dose. 1

For pregnant women:

• Start immediately at full replacement dose targeting TSH <2.5 mIU/L in first trimester. 1, 3
• Increase pre-pregnancy dose by 25-50% immediately upon pregnancy confirmation. 1
• Monitor TSH every 4 weeks during pregnancy. 1

Monitoring Protocol

• Recheck TSH and free T4 at 6-8 weeks after any dose change—this is the time to steady state. 1, 3, 2
• Target TSH 0.5-2.0 mIU/L for primary hypothyroidism. 3
• Once stable, monitor TSH every 6-12 months. 1, 2

---

Subclinical Hypothyroidism (Elevated TSH + Normal Free T4)

Confirm the Diagnosis First

Do not treat based on a single elevated TSH—30-60% normalize spontaneously on repeat testing. 6, 1, 5

• Repeat TSH and free T4 after 3-6 weeks to confirm persistence. 6, 1
• Measure anti-TPO antibodies to identify autoimmune etiology (predicts 4.3% vs 2.6% annual progression risk). 6, 1

Treatment Algorithm by TSH Level

TSH >10 mIU/L with normal free T4:

• Treat all patients regardless of symptoms or age <85 years. 6, 1, 3, 5
• This threshold carries ~5% annual progression risk to overt hypothyroidism and is associated with cardiac dysfunction and adverse lipid profiles. 6, 1, 2
• Evidence quality: Fair. 6, 1
• Start levothyroxine 25-50 mcg daily in elderly/cardiac patients, 75-100 mcg in young healthy adults. 1, 3

TSH 4.5-10 mIU/L with normal free T4:

• Do NOT routinely treat asymptomatic patients—randomized trials show no symptomatic benefit. 6, 1, 5
• Evidence quality: Fair. 6, 1

However, TREAT in these specific situations:

• Pregnant women or planning pregnancy: Treat any TSH elevation, target <2.5 mIU/L first trimester. 6, 1, 3
• Symptomatic patients (fatigue, weight gain, cold intolerance, constipation): Consider 3-4 month trial with clear evaluation of benefit. 6, 1
• Positive anti-TPO antibodies: Higher progression risk justifies treatment. 6, 1
• Goiter or infertility: Treatment reasonable. 6, 3

Patients >85 years with TSH 4.5-10 mIU/L:

• Avoid treatment—12% of those >80 years have TSH >4.5 mIU/L without thyroid disease, and overtreatment risks outweigh benefits. 1

Monitoring Without Treatment

• Recheck TSH every 6-12 months if not treating. 6, 1
• Treat if TSH rises >10 mIU/L or symptoms develop. 6, 1

---

Overt Hyperthyroidism (Suppressed TSH + Elevated Free T4/T3)

Initial Evaluation

• Measure TSH, free T4, free T3, and TSH receptor antibodies (TRAb). 7
• Obtain radioactive iodine uptake scan to distinguish Graves' disease (diffuse uptake) from toxic nodular goiter (focal uptake) from thyroiditis (low uptake). 7
• ECG to screen for atrial fibrillation. 7

Treatment Options

Methimazole (preferred antithyroid drug):

• Initial dose: 10-40 mg daily depending on severity. 8
• Monitor CBC and liver function at baseline and if symptoms develop. 8
• Titrate based on free T4 normalization (TSH lags). 8
• Avoid propylthiouracil except in first trimester pregnancy due to severe hepatotoxicity risk. 8

Propylthiouracil (PTU):

• Use ONLY in first trimester pregnancy (methimazole is teratogenic weeks 6-10). 8
• Dose: 50-150 mg three times daily. 8
• Switch to methimazole after first trimester. 8

Radioactive iodine (RAI):

• Definitive treatment for Graves' disease not achieving remission after 12-18 months of antithyroid drugs. 8
• First-line for toxic nodular goiter. 8
• Contraindicated in pregnancy and breastfeeding. 8
• Expect permanent hypothyroidism requiring lifelong levothyroxine. 8

Thyroidectomy:

• Consider for large goiters with compressive symptoms, suspected malignancy, or patient preference. 8
• Requires lifelong levothyroxine replacement. 8

Special Populations

Atrial fibrillation:

• Treat hyperthyroidism aggressively—most cases convert to sinus rhythm once euthyroid. 7
• Beta-blockers for rate control. 7

Pregnancy:

• PTU first trimester, switch to methimazole second/third trimester. 8
• Target free T4 at upper limit of normal (TSH may be suppressed normally in pregnancy). 8

---

Subclinical Hyperthyroidism (Suppressed TSH + Normal Free T4/T3)

Confirm and Grade Severity

Repeat TSH with free T4 and free T3:

• If TSH 0.1-0.45 mIU/L: Repeat in 3 months (Grade I—mild). 7
• If TSH <0.1 mIU/L: Repeat in 4 weeks (Grade II—severe). 7
• If cardiac disease present: Repeat in 2 weeks regardless of TSH level. 7

Determine Etiology

• Radioactive iodine uptake scan distinguishes Graves' disease, toxic nodular goiter, or thyroiditis. 7
• Check if patient is taking levothyroxine (exogenous vs endogenous cause). 7

Treatment Algorithm

TSH <0.1 mIU/L (Grade II)—TREAT if:

• Age >60 years (3-fold increased atrial fibrillation risk over 10 years). 7
• Cardiac disease or atrial fibrillation (up to 3-fold increased cardiovascular mortality). 7
• Osteoporosis or postmenopausal women (significant bone mineral density loss). 7
• Confirmed Graves' disease or toxic nodular goiter. 7

TSH 0.1-0.45 mIU/L (Grade I):

• Monitor without treatment in most cases—progression to overt hyperthyroidism is rare. 7
• Recheck TSH every 3-12 months until normalization or stabilization. 7
• Consider treatment if symptomatic or high-risk features present. 7

Treatment Options

• Methimazole, radioactive iodine, or surgery depending on etiology (same as overt hyperthyroidism). 7, 8

---

Iatrogenic Subclinical Hyperthyroidism (Levothyroxine Overtreatment)

This is a critical and common problem—approximately 25% of patients on levothyroxine are unintentionally overtreated with suppressed TSH. 1

Risks of TSH Suppression

• **TSH <0.1 mIU/L:** 3-5-fold increased atrial fibrillation risk, 2.2-fold increased all-cause mortality, 3-fold increased cardiovascular mortality (especially age >60). 1, 7
• Osteoporosis and fractures: Significant bone mineral density loss in postmenopausal women. 1, 7
• Cardiac dysfunction: Increased heart rate, left ventricular hypertrophy, diastolic dysfunction. 7

Dose Reduction Strategy

If TSH <0.1 mIU/L:

• Reduce levothyroxine by 25-50 mcg immediately. 1
• Recheck TSH in 6-8 weeks. 1

If TSH 0.1-0.45 mIU/L:

• Reduce levothyroxine by 12.5-25 mcg, especially in elderly or cardiac patients. 1
• Recheck TSH in 6-8 weeks. 1

Exception—Thyroid Cancer Patients:

• Do NOT reduce dose without consulting endocrinologist—intentional TSH suppression may be required. 1
• Target TSH varies by risk: 0.5-2.0 mIU/L (low-risk), 0.1-0.5 mIU/L (intermediate-risk), <0.1 mIU/L (structural incomplete response). 1

---

Special Populations and Considerations

Pregnancy

• Treat any TSH elevation immediately—untreated hypothyroidism increases risk of preeclampsia, low birth weight, miscarriage, and neurodevelopmental deficits. 1, 3
• Target TSH <2.5 mIU/L first trimester, <3.0 mIU/L second/third trimester. 1
• Increase levothyroxine dose 25-50% immediately upon pregnancy confirmation. 1
• Monitor TSH every 4 weeks during pregnancy. 1

Elderly Patients (>70 years)

• Start levothyroxine at 25-50 mcg daily regardless of TSH level to avoid cardiac complications. 1, 3, 5, 2
• Titrate slowly by 12.5-25 mcg every 6-8 weeks. 1
• Accept slightly higher TSH targets (up to 5-6 mIU/L may be acceptable in very elderly). 1

Coronary Artery Disease

• Start levothyroxine at 25 mcg daily—rapid normalization can unmask ischemia or precipitate myocardial infarction. 1, 3, 2
• Increase by 12.5 mcg every 6-8 weeks. 1
• Monitor for angina, dyspnea, or arrhythmias at each visit. 1

Atrial Fibrillation

• Avoid TSH suppression <0.45 mIU/L—this dramatically increases atrial fibrillation risk. 1, 7
• Target TSH 0.5-4.5 mIU/L. 1
• If hyperthyroid, treat aggressively as most convert to sinus rhythm once euthyroid. 7

Osteoporosis

• Avoid TSH suppression—even mild suppression (0.1-0.45 mIU/L) causes significant bone mineral density loss in postmenopausal women. 1, 7
• Ensure adequate calcium (1200 mg/day) and vitamin D (1000 units/day) intake. 1
• Consider bone density assessment if TSH chronically suppressed. 1

---

Common Pitfalls and How to Avoid Them

Do NOT treat based on single abnormal TSH

• 30-60% of elevated TSH values normalize spontaneously—always confirm with repeat testing after 3-6 weeks. 6, 1, 5

Do NOT start thyroid hormone before ruling out adrenal insufficiency

• In central hypothyroidism or autoimmune disease, check morning cortisol/ACTH first—starting levothyroxine can trigger adrenal crisis. 1, 3

Do NOT ignore suppressed TSH in asymptomatic patients

• Even without symptoms, TSH <0.1 mIU/L causes real cardiovascular and bone damage—reduce levothyroxine dose immediately. 1, 7

Do NOT use full replacement dose in elderly or cardiac patients

• Start 25-50 mcg daily and titrate slowly—rapid normalization can cause myocardial infarction or fatal arrhythmias. 1, 3, 2

Do NOT adjust levothyroxine dose before 6-8 weeks

• Levothyroxine has long half-life—adjusting sooner leads to inappropriate dosing and cycling between hypo/hyperthyroidism. 1, 5

Do NOT miss transient thyroiditis

• Recovery phase of thyroiditis can cause elevated TSH for weeks/months—avoid committing patients to lifelong treatment unnecessarily. 1, 5

Do NOT forget medication interactions

• Iron, calcium, proton pump inhibitors, and bile acid sequestrants reduce levothyroxine absorption—take levothyroxine 30-60 minutes before food and 4 hours apart from these medications. 1, 5

Do NOT overlook iodine exposure risk in nodular goiter

• Patients with nodular goiter and low TSH can develop overt hyperthyroidism after iodinated contrast—warn patients and consider prophylactic antithyroid drugs before contrast studies. 7